NTAD: A longitudinal neuroimaging dataset of Alzheimer’s disease pathology
Preprint
Abstract
We introduce the New Therapeutics in Alzheimer’s Disease (NTAD) dataset, a multi-modal and longitudinal imaging dataset from 70 biomarker-positive people with early dementia or Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD), assessed over 2.5 years, and 35 healthy controls assessed at baseline. The data include simultaneous magneto-and electro-encephalography (M/EEG), 3-Tesla structural and functional magnetic resonance imaging (MRI), Amyloid-β positron emission tomography (PET), fluid proteomic biomarkers in cerebrospinal fluid and blood, and a battery of clinical and neuropsychological assessments. 11 C UCB-J PET was undertaken for a subset of participants. For people with AD, assessments were repeated at approximately three weeks, 15 months, and 28 months after baseline. The data can be accessed through the Dementias Platform UK (DPUK), including pre-processed M/EEG and T1 MRI in pseudonymised BIDS format. With the pressing need to develop treatments for slowing, reversing, and preventing AD, these data provide an opportunity for identifying and validating novel biomarkers of Alzheimer’s disease neurophysiology, as well as understanding its treatable pathology.Keywords
Funding Information
- Alzheimer‘s Research UK (ARUK-PG2017B-19)
- Wellcome Trust (103838)
- Wellcome Trust (203139/Z/16/Z)
- Wellcome Trust (203139/A/16/Z)
- Medical Research Council (SUAG/051)
- Medical Research Council (G101400)
- Medical Research Council (SUAG/046 G101400)
- Medical Research Council (SUAG/092 116768)
- Medical Research Council (SUAG/086 G116768)
- Medical Research Council (MC_UU_00030/14)
- NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
- NIHR Cambridge Biomedical Research Centre (NIHR203312)
- NIHR Oxford Biomedical Research Centre (IS-BRC1215-20008)
- NIHR Oxford Health Biomedical Research Centre (IS-BRC1215-20005)
This publication has 62 references indexed in Scilit:
- Alzheimer's disease and its progression reduce pyramidal cell gain and connectivityAlzheimer's & Dementia, 2025
- The PREVENT‐AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyondAlzheimer's & Dementia, 2025
- Neurophysiological Progression in Alzheimer's Disease: Insights From Dynamic Causal Modelling of Longitudinal MagnetoencephalographyHuman Brain Mapping, 2025
- GABAergic modulation of beta power enhances motor adaptation in frontotemporal lobar degenerationAlzheimer's & Dementia, 2025
- Reliability of dynamic causal modelling of resting‐state magnetoencephalographyHuman Brain Mapping, 2024
- Synaptic Loss in Frontotemporal Dementia Revealed by [11C]UCB‐J Positron Emission TomographyAnnals of Neurology, 2022
- Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐JAlzheimer's & Dementia, 2022
- The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screeningInternational Journal of Geriatric Psychiatry, 2006
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991
- Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severityAnnals of Neurology, 1990